Prothena
- Company typePublic
- Founded2012
- HeadquartersSouth San Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Prothena firmographics
Firmographics- Name
- Prothena
- Legal name
- Prothena Corporation plc
- Website
- https://prothena.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Prothena industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals (Neuroscience)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Prothena is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Prothena business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Milestone Payments from Partners: Prothena receives milestone payments from strategic partners upon achievement of clinical, regulatory, and commercial development milestones. Currently earning milestones from Novo Nordisk ($1.2B total potential) and Bristol Myers Squibb partnerships.
- Future Product Revenue: Post-approval, the company will receive royalties and/or milestone payments from partnered programs commercialized by Roche (prasinezumab), Novo Nordisk (coramitug), and Bristol Myers Squibb (BMS-986446). Prothena retains certain co-development rights and potential sales-based payments.
- Clinical Milestones: Near-term revenue opportunity from up to $105 million in aggregate clinical milestone payments from strategic partners Novo Nordisk and Bristol Myers Squibb expected in 2026.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Prothena product offering
Product offeringCore offering
Prothena is a clinical-stage biotechnology company that discovers and develops monoclonal antibody therapeutics targeting misfolded proteins (alpha-synuclein, tau, transthyretin) for neurodegenerative and rare peripheral amyloid diseases including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, and ALS. The company develops its drug candidates through internal discovery and out-licenses them to major pharmaceutical partners (Roche, Novo Nordisk, Bristol Myers Squibb) for clinical development and global commercialization, retaining co-development involvement and milestone/royalty rights.
Product overview
Prothena is a clinical-stage biotechnology company with a diversified pipeline of novel investigational therapies targeting neurodegenerative and rare peripheral amyloid diseases. The company's portfolio includes six key programs: Prasinezumab (Parkinson's disease, partnered with Roche, Phase 3), Coramitug/PRX004 (ATTR amyloidosis, partnered with Novo Nordisk, Phase 3), BMS-986446/PRX005 (Alzheimer's disease, partnered with Bristol Myers Squibb, Phase 2), PRX019 (neurodegenerative diseases, Phase 1), and two preclinical programs (TDP-43 CYTOPE for ALS and PRX012-TfR for Alzheimer's disease). The company leverages deep expertise in protein dysregulation and antibody targeting to develop disease-modifying therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- Prasinezumab
- Coramitug (PRX004)
- BMS-986446 (PRX005)
- PRX019
- TDP-43 CYTOPE Program
- PRX012-TfR
Quantifiable outcome
- Prasinezumab showed slowing of motor progression in rapidly progressing early-stage Parkinson's disease patients in PADOVA Phase 2b trial (Lancet, May 2026)
- +4 more outcomes
Companies that use Prothena
Customer profileSegments4 records
Ideal customer profiles1 record
Prothena technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Prothena partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Academic/Research InstitutionsminorCollaboration with academic researchers and institutions for scientific presentations and research, including presentation of TDP-43 CYTOPE program data at Neuroscience 2025 conference.
- Bristol Myers SquibbcoreGlobal Neuroscience Research and Development Collaboration for BMS-986446 (PRX005) targeting tau for Alzheimer's disease. Bristol Myers Squibb responsible for all communication, development, manufacturing, and commercialization. Phase 2 TargetTau-1 trial fully enrolled. PRX019 also licensed to BMS in 2024 for neurodegenerative diseases.
- Novo NordiskcoreAcquisition agreement where Novo Nordisk acquired worldwide rights to Prothena's ATTR amyloidosis program including coramitug (PRX004). Prothena eligible to receive up to $1.2 billion in milestone payments, with $150 million earned to date. Novo Nordisk leads Phase 3 CLEOPATTRA trial and future global commercialization. FDA Fast Track Designation obtained for coramitug in ATTR-CM.
- RochecoreWorldwide collaboration between Prothena and Roche for prasinezumab (anti-α-synuclein antibody) for Parkinson's disease. Roche leads global clinical development (Phase 3 PARAISO trial ongoing) and commercialization. Prothena co-developed the antibody and receives milestone payments and royalties. This is a flagship partnership for Prothena's lead Parkinson's disease program.
Scale indicators12 records
Recent moves9 records
Expansion highlights5 records
Prothena competitors and assessment
Company assessmentDirect peers
- Wave Life Sciences: Clinical-stage biotech developing oligonucleotide therapeutics for neurological diseases including Huntington's, ALS, and Parkinson's. Comparable size, clinical stage, and focus on hard-to-treat neurological indications.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases using antibody and small molecule approaches targeting lysosomal function and protein aggregation. Closely comparable in size, clinical stage, neurology focus, and partnered model (e.g., Sanofi collaboration).
- Alnylam Pharmaceuticals: Leader in RNA interference therapeutics with Onpattro and Amvuttra approved for ATTR amyloidosis, directly competing with Prothena's coramitug in the same ATTR indication. Comparable in targeting misfolded proteins but with siRNA rather than antibody modality.
- BridgeBio Pharma: Commercial-stage biotech with Attruby (acoramidis) approved for ATTR-CM, directly competing with coramitug. Comparable in indication focus and partnership-heavy development model with multiple partnered programs.
- Ionis Pharmaceuticals: Antisense oligonucleotide platform company with neurology pipeline including TTR amyloidosis (eplontersen, partnered with AstraZeneca) and ALS programs. Comparable in targeting neurological diseases via novel modalities and heavy partnership model.
- Voyager Therapeutics: Clinical-stage gene therapy company focused on neurological diseases including Parkinson's (VY-AADC), ALS, and Huntington's. Comparable in clinical stage, neuroscience focus, and partnership-driven model (e.g., Pfizer, Neurocrine partnerships).
Broad incumbents
- Biogen: Large-cap neurology biotech with Alzheimer's franchise (Leqembi, partnered with Eisai) and broad neurodegenerative pipeline. Comparable to Prothena in disease focus (Alzheimer's, Parkinson's, ALS) but vastly larger and commercially established.
- Eisai: Large Japanese pharma with Leqembi for Alzheimer's, partnered with Biogen. Competes with Prothena's BMS-986446 in tau-targeting for AD. Notably, Prothena's CDO Chad Swanson led lecanemab's clinical development at Eisai.
Emerging players
- Cassava Sciences: Clinical-stage biotech focused on Alzheimer's disease with simufilam in Phase 3. Comparable in clinical-stage neuroscience focus but smaller and single-asset versus Prothena's diversified pipeline.
- Anavex Life Sciences: Clinical-stage biotech developing therapeutics for Alzheimer's, Parkinson's, and Rett syndrome. Comparable in clinical-stage neurology focus and protein-misfolding disease targets but uses small molecules rather than antibodies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Prothena social profiles
Digital presenceProthena financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prothena leadership team
Management profileNumber of profiles
Profiles14 records
Prothena funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prothena M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prothena
What does Prothena do?
Prothena is a clinical-stage biotechnology company that discovers and develops monoclonal antibody therapeutics targeting misfolded proteins (alpha-synuclein, tau, transthyretin) for neurodegenerative and rare peripheral amyloid diseases including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, and ALS. The company develops its drug candidates through internal discovery and out-licenses them to major pharmaceutical partners (Roche, Novo Nordisk, Bristol Myers Squibb) for clinical development and global commercialization, retaining co-development involvement and milestone/royalty rights.
Is Prothena a public or private company?
Prothena is a public company. It is classified as public and is currently operating.
When was Prothena founded?
Prothena was founded in 2012. It employs 101 to 250 people.
Where is Prothena based?
Prothena is headquartered in South San Francisco, United States, in the North America region.
How does Prothena make money?
Three revenue lines are on record. Milestone Payments from Partners are the primary driver. The others are future Product Revenue and clinical Milestones.
Who are Prothena's main competitors?
Direct peers on record are Wave Life Sciences, Denali Therapeutics, Alnylam Pharmaceuticals, BridgeBio Pharma, Ionis Pharmaceuticals and Voyager Therapeutics. Broad incumbents are Biogen and Eisai. Emerging players are Cassava Sciences and Anavex Life Sciences.
Does Prothena have an API?
No public API is recorded for Prothena.
What industry is Prothena in?
Prothena's product category is Clinical-stage Biopharmaceuticals (Neuroscience). Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.